Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice

Bao,Rui; Shui,Xianqi; Hou,Jiong; Li,Jinbao; Deng,Xiaoming; Zhu,Xiaoyan; Yang,Tao

doi:10.3892/ijmm.2016.2679

Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice

Authors:
- Rui Bao
- Xianqi Shui
- Jiong Hou
- Jinbao Li
- Xiaoming Deng
- Xiaoyan Zhu
- Tao Yang
View Affiliations

Affiliations: Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China, Institution of Surgical Teaching and Research, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China, Department of Physiology, Second Military Medical University, Shanghai 200433, P.R. China
Published online on: July 14, 2016 https://doi.org/10.3892/ijmm.2016.2679
Pages: 969-975

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The number of regulatory T cells (Treg cells) and the expression of ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1; also known as CD39) and 5'-ectonucleotidase (NT5E; also known as CD73) on the Treg cell surface are increased during sepsis. In this study, to determine the factors leading to the high expression of CD39 and CD73, and the regulation of the CD39/CD73/adenosine pathway in Treg cells under septic conditions, we constructed a mouse model of sepsis and separated the Treg cells using a flow cytometer. The Treg cells isolated from the peritoneal lavage and splenocytes of the mice were treated with adenosine or the specific adenosine A2A receptor agonist, CGS21680, and were transfected with specific siRNA targeting E2F transcription factor 1 (E2F-1) or cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), which are predicted transcription regulatory factors of CD39 or CD73. The regulatory relationships among these factors were then determined by western blot analysis and dual-luciferase reporter assay. In addition, changes in adenosine metabolism were measured in the treated cells. The results revealed that adenosine and CGS21680 significantly upregulated CD39 and CD73 expression (P<0.01). E2F-1 and CREB induced CD39 and CD73 expression, and were upregulated by adenosine and CGS21680. Adenosine triphosphate (ATP) hydrolysis and adenosine generation were inhibited by the knockdown of E2F-1 or CREB, and were accelerated in the presence of CGS21680. Based on these results, it can be inferred that adenosine, the adenosine A2A receptor agonist, E2F-1 and CREB are the possible factors contributing to the high expression of CD39 and CD73 on the Treg cell surface during sepsis. Adenosine and its A2A receptor agonist served as the signal transducer factors of the CD39/CD73/adenosine pathway, accelerating adenosine generation. Our study may benefit further research on adenosine metabolism for the treatment of sepsis.

View Figures

View References

1	Jawad I, Lukšić I and Rafnsson SB: Assessing available information on the burden of sepsis: Global estimates of incidence, prevalence and mortality. J Glob Health. 2:0104042012. View Article : Google Scholar : PubMed/NCBI
2	Henriksen DP, Laursen CB, Jensen TG, Hallas J, Pedersen C and Lassen AT: Incidence rate of community-acquired sepsis among hospitalized acute medical patients-a population-based survey. Crit Care Med. 43:13–21. 2015. View Article : Google Scholar
3	Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opa SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 39:165–228. 2013. View Article : Google Scholar : PubMed/NCBI
4	Marik PE: Early management of severe sepsis: concepts and controversies. Chest. 145:1407–1418. 2014. View Article : Google Scholar : PubMed/NCBI
5	Kang JH, Super M, Yung CW, Cooper RM, Domansky K, Graveline AR, Mammoto T, Berthet JB, Tobin H, Cartwright MJ, et al: An extracorporeal blood-cleansing device for sepsis therapy. Nat Med. 20:1211–1216. 2014. View Article : Google Scholar : PubMed/NCBI
6	Saito K, Wagatsuma T, Toyama H, Ejima Y, Hoshi K, Shibusawa M, Kato M and Kurosawa S: Sepsis is characterized by the increases in percentages of circulating CD4⁺CD25⁺ regulatory T cells and plasma levels of soluble CD25. Tohoku J Exp Med. 216:61–68. 2008. View Article : Google Scholar : PubMed/NCBI
7	Sakaguchi S, Yamaguchi T, Nomura T and Ono M: Regulatory T cells and immune tolerance. Cell. 133:775–787. 2008. View Article : Google Scholar : PubMed/NCBI
8	Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Höpner S, Centonze D, Bernardi G, Dell'Acqua ML, et al: Expression of ectonucleotidase CD39 by Foxp3⁺ Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood. 110:1225–1232. 2007. View Article : Google Scholar : PubMed/NCBI
9	Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ and Mosmann TR: T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine monophosphate to adenosine. J Immunol. 177:6780–6786. 2006. View Article : Google Scholar : PubMed/NCBI
10	Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, et al: Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 204:1257–1265. 2007. View Article : Google Scholar : PubMed/NCBI
11	Yu Z and Jin T: Extracellular high dosages of adenosine triphosphate induce inflammatory response and insulin resistance in rat adipocytes. Biochem Biophys Res Commun. 402:455–460. 2010. View Article : Google Scholar : PubMed/NCBI
12	Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol (1985). 76:5–13. 1994.
13	Sullivan GW: Adenosine A2A receptor agonists as anti-inflammatory agents. Curr Opin Investig Drugs. 4:1313–1319. 2003.
14	Csóka B, Németh ZH, Törő G, Koscsó B, Kókai E, Robson SC, Enjyoji K, Rolandelli RH, Erdélyi K, Pacher P, et al: CD39 improves survival in microbial sepsis by attenuating systemic inflammation. FASEB J. 29:25–36. 2015. View Article : Google Scholar :
15	Haskó G, Csóka B, Koscsó B, Chandra R, Pacher P, Thompson LF, Deitch EA, Spolarics Z, Virág L, Gergely P, et al: Ecto-5′-nucleotidase (CD73) decreases mortality and organ injury in sepsis. J Immunol. 187:4256–4267. 2011. View Article : Google Scholar
16	Rittirsch D, Huber-Lang MS, Flierl MA and Ward PA: Immuno-design of experimental sepsis by cecal ligation and puncture. Nat Protoc. 4:31–36. 2009. View Article : Google Scholar
17	Busse M, Traeger T, Pötschke C, Billing A, Dummer A, Friebe E, Kiank C, Grunwald U, Jack RS, Schütt C, et al: Detrimental role for CD4⁺ T lymphocytes in murine diffuse peritonitis due to inhibition of local bacterial elimination. Gut. 57:188–195. 2008. View Article : Google Scholar
18	Eltzschig HK, Köhler D, Eckle T, Kong T, Robson SC and Colgan SP: Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood. 113:224–232. 2009. View Article : Google Scholar :
19	Chalmin F, Mignot G, Bruchard M, Chevriaux A, Végran F, Hichami A, Ladoire S, Derangère V, Vincent J, Masson D, et al: Stat3 and Gfi-1 transcription factors control Th17 cell immuno-suppressive activity via the regulation of ectonucleotidase expression. Immunity. 36:362–373. 2012. View Article : Google Scholar : PubMed/NCBI
20	Bellingan G, Maksimow M, Howell DC, Stotz M, Beale R, Beatty M, Walsh T, Binning A, Davidson A, Kuper M, et al: The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: An open-label study. Lancet Respir Med. 2:98–107. 2014. View Article : Google Scholar : PubMed/NCBI
21	Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB and Robson SC: CD39 and control of cellular immune responses. Purinergic Signal. 3:171–180. 2007. View Article : Google Scholar
22	Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC and Colgan SP: Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med. 200:1395–1405. 2004. View Article : Google Scholar : PubMed/NCBI
23	Wan W, Sutherland GR and Geiger JD: Binding of the adenosine A2 receptor ligand [3H]CGS 21680 to human and rat brain: Evidence for multiple affinity sites. J Neurochem. 55:1763–1771. 1990. View Article : Google Scholar : PubMed/NCBI
24	Antonioli L, Pacher P, Vizi ES and Haskó G: CD39 and CD73 in immunity and inflammation. Trends Mol Med. 19:355–367. 2013. View Article : Google Scholar : PubMed/NCBI
25	Saldanha-Araujo F, Ferreira FI, Palma PV, Araujo AG, Queiroz RH, Covas DT, Zago MA and Panepucci RA: Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes. Stem Cell Res (Amst). 7:66–74. 2011. View Article : Google Scholar
26	Botta Gordon-Smith S, Ursu S, Eaton S, Moncrieffe H and Wedderburn LR: Correlation of low CD73 expression on synovial lymphocytes with reduced adenosine generation and higher disease severity in juvenile idiopathic arthritis. Arthritis Rheumatol. 67:545–554. 2015. View Article : Google Scholar
27	Grünewald JK and Ridley AJ: CD73 represses pro-inflammatory responses in human endothelial cells. J Inflamm (Lond). 7:102010. View Article : Google Scholar
28	Alam MS, Kurtz CC, Rowlett RM, Reuter BK, Wiznerowicz E, Das S, Linden J, Crowe SE and Ernst PB: CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J Infect Dis. 199:494–504. 2009. View Article : Google Scholar : PubMed/NCBI
29	Martin C, Leone M, Viviand X, Ayem ML and Guieu R: High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit Care Med. 28:3198–3202. 2000. View Article : Google Scholar : PubMed/NCBI
30	Alam MS, Kurtz CC, Wilson JM, Burnette BR, Wiznerowicz EB, Ross WG, Rieger JM, Figler RA, Linden J, Crowe SE and Ernst PB: A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4⁺ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. Mucosal Immunol. 2:232–242. 2009. View Article : Google Scholar : PubMed/NCBI
31	Moore CC, Martin EN, Lee GH, Obrig T, Linden J and Scheld WM: An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models. BMC Infect Dis. 8:1412008. View Article : Google Scholar : PubMed/NCBI
32	Sullivan GW, Fang G, Linden J and Scheld WM: A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J Infect Dis. 189:1897–1904. 2004. View Article : Google Scholar : PubMed/NCBI